Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 5, 2012

View Archived Issues

Mitsubishi Tanabe Pharma offers overview of second quarter 2012

Encouraging phase III results presented for Biocon's insulin biosimilar

Cubist Pharmaceuticals begins phase III program for CB-5945

European Commission denies marketing authorization for taliglucerase alfa

Phase I results reported for ICT-107 in glioblastoma multiforme

British and French group presents novel vaccines for AIDS

Qilu Pharmaceutical discloses novel EGFR inhibitors

Shanghai Allist Pharmaceutical patents new PI3K inhibitors

Novel tyrosine-protein kinase inhibitors prepared at Pharmascience

Phase II study of GS-7340 meets 24-week primary objective

Lundbeck prepares new antibodies for Alzheimer's disease

New CSF-1 receptor inhibitors divulged by Pharmascience

Sanofi presents pipeline highlights of third quarter 2012

Degarelix evaluated in women undergoing in vitro fertilization

Immune Response BioPharma publishes full results from phase III study of HIV vaccine

Vertex enters agreements for VX-135 combination studies

Lisdexamfetamine mesilate proves beneficial in cognitively impaired MS patients

FDA requests additional information in CRL for lixivaptan NDA

AlphaCore obtains EMA orphan drug designation for ACP-501

Aerie reports topline data from phase IIa studies of its ROCK inhibitors

Glybera gene therapy approved by the European Commission

Hutchison MediPharma begins phase I study of novel EGFR inhibitor

BAX B-01 shows promise in model of proliferative nephritis

Phase III trial of Adcetris in advanced Hodgkin's lymphoma begins

Keryx Biopharmaceuticals commences phase II study of Zerenex

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...
Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent
BioWorld Science
Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...